Effects of dopamine antagonists on changes in spontaneous EEG and locomotor activity in ketamine-treated rats

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 1-2, 1997, Pages 361-365

  Yamamoto, M ^a   Mizuki, Y ^b   Suetsugi, M ^b   Ozawa, Y ^a   Ooyama, M ^a   Suzuki, M ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Delirium; Dopamine antagonists; EEG; Haloperidol; Ketamine; Locomotor activity; Nemonapride

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; EMONAPRIDE; HALOPERIDOL; KETAMINE;

ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DELIRIUM; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; IRRITABILITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; CEREBRAL CORTEX; DOPAMINE ANTAGONISTS; DRUG EVALUATION, PRECLINICAL; ELECTROENCEPHALOGRAPHY; HALOPERIDOL; HIPPOCAMPUS; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0030911812     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00304-8     Document Type: Article

References (41)

1. Bacopoulos, N. G.; Redmond, D. E.; Roth, R. H. Serotonin and dopamine metabolities in brain regions and cerebrospinal fluid of a primate species: effects of ketamine and fluphenazine. J. Neurochem. 32:1215-1218; 1979.
2. Becsey, L.; Malamed, S.; Radnay, P.; Foldes, F. F. Reduction of the psychotomimetic and circulatory side-effects of ketamine by droperidol. Anesthesiol. 37:536-542; 1972.
3. Bennett, D. A.; Bernard, P. S.; Amrick, C. L. A comparison of PCP-like compounds for NMDA antagonisms in two in vivo models. Life Sci. 42:447-4354; 1988.
4. Christie, M. J.; James, L. B.; Beart P. M. An excitant amino acid projection from the medial prefrontal cortex to the anterior part of nucleus accumbens in the rat. J. Neurochem. 34:477-482; 1984.
5. Dimpfel, W.; Spuler, M. Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely movingrat in the same way as activation of dopaminergic transmission. Psychopharmacol. 101:317-323; 1990.
6. Domino, E. F.; Chodoff, P.; Corssen, G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6:279-291; 1965.
7. Fish, D. N. Treatment of delirium in the critically ill patient. Clin. Pharm. 10:456-466; 1991.
8. Gross, M. M.; Goodenough, D.; Tobin, M.; Halpert, E.; Lepore, D.; Peristein, A.; Sirotoa, M.; Dibianco, J.; Fuller, R.; Kisherner, I. Sleep disturbance and hallucinations in acute alcoholic psychosis. J. Nerv. Menta. Dis. 142:493-514; 1966.
9. Hetzler, B. E.; Wautlet, B. S. Ketamine-induced locomotion in rats in an open-field. Pharmacol. Biochem. Behav. 11:653-655; 1985.
10. Irifune, M.; Shimizu, T.; Nomoto M. Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol. Biochem. Behav. 40:399-407; 1991.
11. 3H-PCP binding. Pharmacol. Biochem. Behav. 22:731-735; 1985.
12. Johnson, J. C. Delirium in the elderly. Emerg. Med. Clin. 8:255-265; 1990.
13. Koek, W.; Colpaert, F. C.; Woods, J. H.; Kamenka, J. M. The phencyclidine (PCP) analog N-[2-benzo(b)thiophenyl)cyclohexyl-]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. J. Pharmacol. Exp. Ther. 250:1019-1027; 1989.
14. Kijima, T.; Atsumi, Y.; Ichise, K.; Uchiyama, M. A polysomnographic study of the delirious state caused by administration of biperidine. Psychol. Med. 25:197-206; 1983 (in Japanese).
15. Koponen, H.; Partanenm, J.; Paarkkonen, A.; Mattila, E.; Riekkinen, P. J. EEG spectral analysis in delirium. J. Neurol Neurosurg. Psychiatr. 52:980-985; 1989.
16. Leuchter, A. F.; Jacobson, S. A. Quantitative measurement of brain electrical activity in delirium. Int. Psychogeriatr. 3:231-247; 1991.
17. Lipowski, Z. J. Delirium in geriatric patients. In: Delirium: Acute confusional states. Oxford University Press, New York, pp. 413-441; 1990a.
18. Lipowski, Z. J. Clinical feature, course, and outcome. In:Delirium: Acute confusional states, Oxford University Press, New York, pp. 54-70; 1990b.
19. Martin, D.; Lodge, D. Ketamine acts as a noncompetitive N-methyl-d-aspartate antagonist on frog spinal cord in vitro. Neuropharmacol. 24:999-1003; 1985.
20. Mattia, A.; Marquis, K. L.; Leccese, A. P.; E-Fakahany, E. E.; Moreton, J. E. Electroencephalographic, behavioral and receptor binding correlates of phencyclinoids in the rat. J. Pharmacol. Exp. Ther. 246:797-802; 1988.
21. Myslobodsky, M.; Ackermann, R. F.; Mansour, R.; Golovehinsky, V. Ketamine-induced rotation and its interaction with naloxone in rats. Brain Res. 172:191-195; 1979.
22. Paxinos, G.; Watson, C. The rat brain in stereotaxic coordinates. Second Edition, Academic Press; 1986.
23. Sagratella, S.; Scotti de C. A.; Pezzola, A.; Popoli, P. Behavioural and electroencephalographic interactions between haloperidol and PCP/sigma ligands in the rat. Psychopharmacol. 105:485-491; 1991.
24. Sagratella, S.; Pezzola, A.; Popoli, P.; de Carolis, A. S. Different capability of N-methyl-d-aspartate antagonists to elicit EEG and behavioural phencyclidine-like effects in rats. Psychopharmacol. 109:277-282; 1992.
25. Santos, A. B.; Wohlreich, M. M.; Pinosky, S. T. Managing agitation in the critical care setting. J. S. C. Med. Assoc. 88:386-391; 1992.
26. Smith, D. J.; Azzaro, A. J.; Turndorf, H.; Abbott S. B. The effect of ketamine HCl on the in vitro metabolism of norepinephrine in rat cerebral cortex tissue. Neuropharmacol. 14:473-481; 1975.
27. Smith, D. J.; Azzaro, A. J.; Zaldivar, S. B.; Palmer, S.; Lee, H. S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacol. 20:391-396; 1981.
28. Snell, L. D.; Mueller, Z. L.; Gannon, R. L.; Silverman, P. B.; Johnson, K. M. A comparison between classes of drugs having phencyclidine-like behavioural properties on dopamine efflux in vitro and dopamine metabolism in vivo. J. Pharmacol. Exp. Ther. 231:261-269; 1984.
29. Sturgeon, R. L.; Fessler, R. G.; London, S. F.; Meltzer, H. Y. A comparison of the effects of neuroleptics on phencyclidine-induced behaviors in the rat. Eur. J. Pharmacol. 76:37-53; 1981.
30. Tachibana, M.; Tanaka, K.; Hishikawa, Y.; Kaneko, Z. A sleep study of acute psychotic states due to alcohol and meprobamate addiction. Adv. in Sleep Res., 2:177-205, Spectrum, New York; 1975.
31. Takahaski, Y.; Kojima, T.; Atsumi, Y. A polygraphic study of delirious state caused by anticholinergic drugs in the course of depression. Folia Psychiatr. Neurol. Jpn., 35:400-427; 1981.
32. Thomson, A. M.; West, D. C.; Lodge, D. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: A site of action of ketamine? Nature 313:479-481; 1985.
33. Trepacz, P. T.; Sclabassi, R. J.; von Thiel, D. H. Delirium: a subcortical phenomenon? J. Neuropschiatr. Clin. Neurosci. 1:283-290; 1989.
34. Tricklebank, M. D.; Singh, L.; Oles, R. J.; Preston, C.; Iversen, S. D. The behavioural effects of MK-801: A comparison with antagonists acting noncompetitively and competitively the NMDA receptor. Eur. J. Pharmacol. 167:127-135; 1989.
35. Trzepacz, P. T.; Leavitt, M.; Ciongoli, K. An animal model for delirium. Psychosomatics 33:404-415; 1992.
36. Tune, L. E.; Bylsma, F. W. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int. Psychogeriatr. 3:397-408; 1991.
37. Usuda, S.; Nishikori, K.; Noshiro, O.; Maeno, H. Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4- methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. Psychopharmacol. 73:103-109; 1981.
38. Vargiu, L.; Stefanini, E.; Musinu, C.; Saba, G. Possible role of brain serotonin in the central effects of ketamine. Neuropharmacol. 17:405-408; 1978.
39. White, P. F.; Way, W. L.; Trevor, A. J. Ketamine - Its pharmacology and therapeutic uses. Anesthesiol. 56:119-136; 1982.
40. Yamamoto, M.; Usuda, S.; Tachikawa, S.; Maeno, H. Pharmacological studies on a new benzamide derivative, YM-09151-2, with potential neuroleptic properties. Neuropharmacol. 21:945-951; 1982.
41. Ylitalo, P.; Saarnivaara, L.; Ahtee, L. Effect of ketamine anesthesia on the content of monoamines and their metabolities in the rat brain. Acta Anaesth Scand. 20:216-220; 1976.